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Haemostasis is a complex process affected by many factors including both cellular and plasma components. It is a
multistep process starting with platelet adhesion to damaged endothelium and ending in clot fibrinolysis. There are
several methods available to study different aspects of haemostasis including adhesion, aggregation, coagulation
and fibrinolysis. This review describes the different methods, what aspects of haemostasis they measure and their
limitations. Methods discussed include methods to study adhesion (e.g. PFA-100, cone and platelet(let) analyzer and
perfusion chambers) and aggregation (e.g. Multiplate, VerifyNow and Plateletworks). Furthermore the principles
behind viscoelastic haemostatic assays are presented as well as methods that can analyse aspects of haemostasis in
plasma or platelet-rich-plasma samples (thrombin generation, overall haemostasis potential and Thrombodynamics
Analyzer).
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Haemostasis is a complex process involving adhesion of
platelets to damaged endothelium, formation of a plate-
let plug (aggregation), formation of a fibrin network to
stabilise the plug, clot retraction and finally fibrinolysis.
In addition all of these processes take place under flow
and is controlled and regulated by factors released from
the surrounding endothelium. Surgery may cause coagu-
lopathy due to acidosis, hypothermia and haemodilution
and is associated with increased fibrinolytic activity which
warrants monitoring to guide transfusion therapy [1,2].
Thus an “ideal” haemostasis assay should preferably
measure all these processes at relevant shear conditions
and provide results in a timely manner. Indeed, there are
many different methods available for measuring one or
more of the many diverse events of the haemostatic
process and platelet function. However, none of the
methods currently available measures all these processes
and they all have their pros and cons. This review will
describe a number of assays used for evaluation of differ-
ent aspects of haemostasis from a technical point of
view, highlighting their methodology and what they can* Correspondence: sofia.ramstrom@liu.se
3Department of Clinical and Experimental Medicine, Linköping University,
Linköping, Sweden
Full list of author information is available at the end of the article
© 2015 Tynngård et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and cannot measure, with conclusions summarized in
Table 1.Tests of primary haemostasis
Aggregometry
In addition to the classical light transmission aggrego-
metry that requires preparation of platelet-rich plasma,
thus limiting its usefulness in the acute clinical setting,
commercial tests for assessment of aggregation in whole
blood have been launched. In general, the tests have
been designed to monitor treatment response to the
common classes of anti-platelet drugs, aspirin, P2Y12
(ADP- receptor) - antagonists and GPIIb/IIIa antagonists
by adding arachidonic acid, ADP or a strong platelet
agonist such as the thrombin PAR1 receptor-activating
peptide (TRAP, amino acid sequence SFLLRN) or colla-
gen, respectively.
In the Multiplate® (Roche, Switzerland) [3] the blood
sample (anticoagulated with citrate or hirudin) is added
to a disposable cuvette containing electrodes to which
platelets adhere and aggregate following addition of col-
lagen, TRAP, ADP, arachidonic acid or ristocetin. This
causes a change in impedance which is registered. Multi-
plate is designed to measure aggregation in whole blood
but can be used on platelet suspensions [4].ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Aspects of global haemostasis assays
Assay Sample type Adhesion Aggregation Coagulation Endothelium Shear No. of citations
Plasma PRP WB Init. Prop. Elast. Lysis
Multiplate - + + - + - - - - - - 250
VerifyNow - - + - + - - - - - - 476
Plateletworks - - + - + - - - - - - 26
Impact-R - - + + + - - - - - + 121
PFA-100 - - + + + - - - - - + 745
Perfusion chambers - - + + + (+) (+) - - (+) + 630
TEG (+) + + - - - + + + - - 4016
ROTEM (+) + + - - - + + + - - 3932
ReoRox (+) + + - - + + + + - - 28
Sonoclot (+) + + - - + + + + - - 113
Thrombin generation + + − - - + + − − - - 118
OHP + − − - - + (+) - + - - 23
Thrombodynamics + + + - - + + − − - - 11
The assays ability to measure adhesion, aggregation, coagulation in terms of initiation (Init.), propagation (Prop.), clot elasticity (Elast) and fibrinolysis (Lysis). The
table shows the type of sample (plasma, platelet-rich-plasma (PRP) or whole blood (WB)) that can be assessed in each assay. The table also shows if the measurement
can include the contribution by endothelium and shear components. Plus (+) means yes and minus (−) means no, signs within parentheses means possible in theory,
but not commonly used. For the propagation component, the perfusion chambers and the Thrombodynamics detects spatial clot propagation, whereas the other
techniques detects other processes occurring after the initial clotting and first fibrin fibres have formed as propagation. To reflect how common these different assays
are, we present the number of citations found on PubMed on the 30th of November 2014.
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cartridge-based instrument for assessment of antiplatelet
medications, with three types of test cartridges, contain-
ing ADP, arachidonic acid or TRAP. Citrated whole
blood is mixed with the platelet agonist and fibrinogen-
coated beads. Activated platelets will bind to the beads
and agglutinate and the increase in light transmittance
due to this will be recorded [5].
The Plateletworks® (Helena Laboratories, USA) ag-
gregation kits are based upon comparing platelet
counts within a control EDTA tube and after aggrega-
tion with ADP, arachidonic acid or collagen within
citrated tubes. Results are expressed as % aggregation
or % inhibition [6].
Over the past years a number of studies have been try-
ing to establish the optimal test and range of platelet re-
activity associated with the highest protection against
thrombosis and the lowest risk of bleeding. The reported
correlation between on-treatment platelet reactivity and
outcome also suggested the use of platelet function
testing to personalize antiplatelet therapy. Several
studies have also been conducted in this field, but
major clinical trials have failed to demonstrate a bene-
fit of such a strategy in improving clinical outcomes
(recently reviewed by [7,8]).
Adhesion assays
The classical adhesion test is to count platelets before and
after passage of heparinised blood through a column filled
with glass beads. Commercially available instrumentsinclude the platelet function analyzer 100 (PFA-100®,
Siemens Healthcare Diagnostics Inc., USA) and the
cone and plate(let) analyzer (CPA) called Impact-R®
(DiaMed, Switzerland). Both of these tests measure
platelet adhesion and aggregation under conditions of
high shear and require anti-coagulated whole blood
[9,10]. The PFA-100 measures the time to occlusion
(CT, closure time) of blood flow through a collagen
coated membrane in the presence of epinephrine or
ADP. In the CPA system the sample is added to a
polystyrene well and plasma proteins adheres to the
surface of the well. Shear stress is applied by rotating
a conical device immersed in the sample, leading to
adhesion and aggregation of platelets. The platelets
are visualized and quantified by staining. The results
are expressed as percentage of surface covered by
aggregates (SC) and average aggregate size (AS) [11].
The PFA-100 and the CPA have been shown to detect
wWF disorders [3,9,12] and GPIIb/IIIa inhibitors
[6,10]. There are also other instruments where shear
can be applied, either using the cone-and-plate tech-
nology or the coaxial cylinder coquette, where the
blood is placed between two coaxial cylinders where
the inner one rotates to generate the shear [13].
Platelet adhesion can also be analysed using perfusion
chambers [14]. The perfusion system consists of two
parallel plates. One of the plates accepts a glass coverslip
that can be coated with proteins, e.g. fibrinogen, collagen,
vWF, laminin, or with endothelial cells. Platelet surface
coverage, aggregate size and platelet rolling velocities can
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The shear can be varied which allows the coagulation
process to be studied under physiological flow conditions.
Ready-made flow chambers, sometimes also offering inte-
grated pump-, imaging- and/or analysis systems are now
entering the market [15]. The use of flow-based assays for
assessment of haemostasis has been recently reviewed
by the ISTH SSC Biorheology Subcommittee [13,16]. As
platelet adhesion in flow-based devices require the pres-
ence of red blood cells, platelet suspensions such as plate-
let concentrates for transfusion cannot be easily evaluated.
Therefore, we have recently proposed a novel assay where
platelet activation upon adhesion to protein-coated beads
can be studied using flow cytometry [17].
Tests of secondary/global haemostasis
Viscoelastic haemostatic assays (VHA)
The viscosity of the blood increases as the fibrin network
forms during blood coagulation. Viscoelastic assays en-
ables analysis of clot formation, clot elasticity development
and the fibrinolysis process in real time. The elasticity of
the clot depends on several factors; the contractile force
exerted by the platelets during clot retraction, platelet con-
centration [18-20], haematocrit [18,21], fibrinogen con-
centration [18-20,22], FXIII [23,24] and the thrombin
generation during coagulation [25]. However, it is import-
ant to emphasize that the major signal comes from platelet
contractile forces and not from the fibrin network [26,27].
Thromboelastography was first described by Hartert in
1948 [28]. There are two commercial thromboelastographs,Figure 1 The measuring principle of TEG (A), ROTEM (B) and ReoRox
cup containing the blood sample. The cup rotates back and forth 4.75° eve
form between the pin and the wall of the cup which will affect the movem
ROTEM instrument, the cup is stationary and a ball-bearing pin rotates bac
spring. Also here fibrin strands will form between the wall of the cup and t
the movement of the pin. In the ReoRox, the cup is turned up every 2.5 se
longitudinal axis. An optic sensor records the frequency and damping of the
fibres formed during coagulation will couple the cup to the bob, and the am
frequency and damping of the oscillation.TEG® (Haemonetics, USA) and ROTEM® (Pentapharm,
Switzerland). The measuring unit of both instruments con-
sists of a cylindrical cup, made of disposable plastic. A pin
is suspended into the cup, and the pin is connected to a de-
tector. The cup and the pin will make a forced oscillation
relative each other with an angle of 4.75° (Figure 1) [25,29].
It is not possible to measure the blood viscosity or to detect
the initiation of coagulation, as the first signals appear when
the pin is connected via the first fibrin fibres spanning the
whole distance to the wall of the cup. The clot elasticity is
expressed in mm in the tracing (Figure 2). The major differ-
ence between the instruments lies in the oscillation. In the
TEG instrument the cup oscillates and in the ROTEM in-
strument the pin oscillates. The ROTEM instrument has
an electronic pipette connected to the instrument to sim-
plify pipetting of the different reagents provided, and the
software provides exact step-by-step instructions to make
the instrument easy to use.
Free oscillation rheometry (FOR) (MediRox AB, Sweden)
is a newer technology which makes it possible to measure
changes in viscosity and elasticity in clotting whole blood
and in dissolving clots and to obtain results in SI-units. In
this instrument (ReoRox®), oscillation is initiated by a forced
turn of the sample cup every 2.5 seconds (Figure 1). After a
brief hold time, the sample cup is released, allowing free ro-
tational oscillation around the longitudinal axis. An optic
angular sensor records the frequency and damping of the
oscillation as a function of time. FOR analysis includes sim-
ultaneous measurement of blood viscosity and thus allows
detection even of the initial phases of coagulation, beforeFOR (C). In the TEG instrument, a pin is suspended by a wire into a
ry 10 seconds. During coagulation of the sample, fibrin strands will
ent of the cup which is gradually transmitted to the pin. In the
k and forth 4.75°. The movement of the pin is driven by an elastic
he pin during coagulation and the strength of the strands will affect
conds and then released, allowing rotational oscillation around the
oscillation. A pin (bob) is immersed into the cup via a shaft. The fibrin
ount and activity of platelets bound to the fibrin network, will affect the
Figure 2 Tracings from TEG (A), ROTEM (B) and ReoRox (C, D) with analysis variables depicted. Clotting time as detected by TEG and
ROTM (R, CT, respectively) and by ReoRox (COT1 and COT2). The elasticity propagation variable by the instruments (alfa by TEG and ROTEM and
Slope by ReoRox). The maximum clot strength (MA by TEG, MCF by ROTEM and G'max by ReoRox). Fibrinolysis variables are LY30 by TEG, LI30 by
ROTEM, and Clot SR and Lysis start and T completion (complete fibrinolysis) by ReoRox.
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plating of the cylindrical cup and the bob immersed in
the centre is used to ensure strong, covalent binding
of fibrinogen to the cup and bob. This prevents de-
tachment when platelet contractile forces are increas-
ing during clot retraction, which has been suggestedFigure 3 Contribution of platelets and fibrinolysis to the decrease in
curve amplitude (left) or FOR G’ (right) occur even in the presence of trane
induced by added t-PA (light grey curve). On the contrary, the decrease wa
(PFP, dark grey curve).as a potential problem in TEG and ROTEM [30]. Po-
tential detachment, as well as differences in oscillation
and detection strategies may be partial explanations to
why the difference between platelet-free plasma and
whole blood is smaller in ROTEM than in FOR (see
Figure 3).ROTEM® or FOR curves. In normal individuals, the decrease in ROTEM
xamic acid (Cyklokapron®) in doses capable of preventing fibrinolysis
s platelet-dependent, as it was totally absent in platelet free plasma
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ing on different aspects of the coagulation process
(Table 2). The tests commercially available for TEG use
kaolin or a combination of kaolin and tissue factor (TF)
to activate intrinsic or extrinsic pathway of coagulation,
respectively [31]. ROTEM also has reagents that can ac-
tivate the intrinsic or extrinsic pathway. Both systems
have tests to monitor treatment with heparin and pro-
tamine [32] as well as for evaluation of the contribution
of fibrin to the clot strength [31,33]. None of the above
tests can be used to monitor anti-platelet treatment with
ADP-receptor inhibitors or aspirin. The PlateletMap-
ping™ assay was introduced to monitor anti-platelet ther-
apy by TEG. A native blood sample activated by kaolin
is compared with heparinised samples where the fibrin
network is formed by adding reptilase and FXIIIa and
the platelets are activated by ADP or arachidonic acid
[34]. This test predicted a first ischemic event after elect-
ive stenting in patients with coronary artery disease on
clopidogrel and aspirin [35]. TEG has been used to
monitor blood component therapy in patients undergo-
ing cardiac, liver, or trauma surgery [36-39]. Treatment
algorithms have been developed to interpret the results
and guide treatment with blood components [31,33,40].
Low clot strength in trauma patients is associated with
increased mortality [39]. For the FOR, there is a panel of
tests available including tests to monitor heparin treat-
ment and for evaluation of the contribution of fibrin to
the clot strength. The coagulation is activated via the ex-
trinsic pathway or by addition of a specific PAR1-
activating peptide in the TRAP test to activate platelets
via thrombin receptor PAR1.The instrument has mainly
been used for studies of the platelet contribution to
whole blood coagulation and quality control of plateletTable 2 TEG, ROTEM and ReoRox assays
TEG ROTEM
KaolinTEG InTEM
Kaolin (intrinsic pathway activation) Intrinsic pathway activation, sensitive
HepTEG HepTEM
Heparin neutralising cup Intrinsic pathway activation + hepari
RapidTEG ExTEM
Kaolin + TF activation TF activation (extrinsic pathway)
Functional fibrinogen TEG (FFTEG) FibTEM
TF activation + platelet inhibition with
abciximab
TF activation + platelet inhibition wit
FibTEM+
TF activation + platelet inhibition wit
(under development)
Platelet Mapping Kit ApTEM
(ADP, AA) (TF activation + aprotinin, verification
TEG, ROTEM and ReoRox assays and their respective sensitivities and clot initiatingconcentrates [18,41-44]. The clinical studies published
so far have been limited in number [45-48]. FOR reports
a wider measuring range for elasticity as compared to
thromboelastography [18,49]. As an example, in preg-
nancy the increase in clot elasticity was significant
already in the first trimester utilising FOR, with an grad-
ual increase to 52% in the third trimester [47], while no
significant changes in maximal amplitude between tri-
mesters were detected using TEG, and the maximum in-
crease during pregnancy was less than 8% [50].
TEG and ReoRox uses abciximab, which blocks the
binding of fibrinogen to the GPIIb receptor, to evaluate
the contribution of fibrin to the clot strength whereas
ROTEM uses cytochalasin D which inhibits the reorga-
nisation of the platelet cytoskeleton. However, it has
been shown that these substances alone might not com-
pletely block the platelet contribution to the clot
strength [26] and that a combination of cytochalasin D
and abciximab or tirofiban (similar mechanism of action
as abciximab) more effectively blocks platelets [51].
The VHA instruments usually operate at 37°C but the
temperature can be adjusted. This allows coagulation to
be monitored in patients with hypothermia which is im-
portant since hypothermia affects coagulation [24].
Hyperfibrinolysis during trauma or major surgery is an
important therapeutic target in bleeding management.
VHA can be used to detect fibrinolysis by measuring the
reduction in elasticity (Figure 2). However, it is import-
ant to recognise that under normal conditions, the
“lysis” parameter in these instruments does not reflect
ongoing fibrinolytic activity in the sample, but instead
mirrors the decrease in platelet contractile force, prob-
ably due to exhaustion, as this decrease is also seen in
samples treated with the fibrinolysis inhibiting drugReoRox
HepScreen1
to heparin TP (extrinsic pathway, sensitive to
heparin)
HepScreen2





h cytochalasin TP activation + platelet inhibition with
abciximab)
h cytochalasin and tirofiban
ReoTrap
of fibrinolysis) PAR-1 activation
substances. Tissue factor (TF), thromboplastin (TP).
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the VHA can influence the ability of the VHA to detect
fibrinolysis [52,53]. For example, RapidTEG was shown
to be less sensitive than kaolin TEG to low fibrinolytic
activity [52]. It has been pointed out that currently avail-
able assays to TEG and ROTEM are insufficient to de-
tect low increase in fibrinolytic activity [54]. FOR can
also detect increasing fibrinolytic activity by measuring
changes in viscosity when the blood reverts back into li-
quid form (Figure 2) [53]. VHAs have been used to as-
sess the effects of haemodilution with Ringer’s actetate,
hydroxylethyl starch (HES) and albumin on coagulation
and treatment with fibrinogen and FXIII concentrates
in vitro [23,24,27,55,56].
The Sonoclot® analyser (Sienco, Inc., USA) has a tubu-
lar probe that oscillates up and down in the whole blood
sample. The resistance to movement is measured and re-
corded during the coagulation process [57]. Since the
introduction in the 70’s [58], the use of Sonoclot® has
been relatively limited as compared to TEG and
ROTEM.
Other whole blood tests
A number of other approaches to evaluate “global
haemostasis” have been described and commercialised,
but not gained widespread interest. However, as it may
be interesting to discuss their methodology, we will de-
scribe them briefly in this section.
The Clot Signature Analyzer™ (CSA™; Xylum Corporation,
USA) is a global haemostasis screening instrument
intended for use with native whole blood [59]. The
blood is passed through a thin plastic tube under pres-
sure. Two holes are then punched in the tube, causing
a fall in pressure. The platelet and fibrin clot will plug
the holes and this time is recorded as the “platelet
hemostasis time” (PHT). The CSA also records the clot
time (CT) as the coagulation spreads though the lumen
of the tube. A subsample of the blood is also passed
through a second tube with collagen fibrils and the
time to reach a 50% pressure reduction in this tube is
called collagen-induced thrombus formation time (CITF).
Despite a relatively good sensitivity in picking out patients
with known bleeding disorders in a multi-centre trial [60],
the test could not help in distinguishing between platelet
and coagulation factor defects.
The Gorog Thrombosis Test (GTT) [61] or throm-
botic status analyser (TSA) [62] (Montrose Diagnostics,
UK) adds native blood to a vertical conical tube with a
hole in the bottom. The tube also contains two steel
balls. Platelets are activated by shear stress (175 dyne/
cm2) when they pass the first large ball, and will then ag-
gregate and initiate coagulation in the area between the
balls. A light sensor records the time between blood
droplets leaving the end of the tube to determine thetime for occlusion, and the time for thrombolysis when
blood flow starts again.
The Hemostasis Analysis System (HAS; Hemodyne,
Inc., USA) is measuring the force developed by plate-
lets as they undergo cellular contraction (“platelet
contractile force”, PCF™), and speed of clot formation
in whole blood between a cup and parallel upper plate
at 37°C [63]. The time between assay start and PCF
onset is termed the thrombin generation time (TGT™)
and is used as a surrogate marker for thrombin gener-
ation [64].
The HemoSTATUS™ test or “platelet-activated clotting
time” (Medtronic Blood Management, USA) measures
acceleration of kaolin-activated clotting time (ACT) by
different concentrations of platelet activating factor
(PAF). The test has mainly been used for the evaluation
of patients during cardiac surgery [65,66], even though
its usefulness for predicting blood loss has been ques-
tioned [67,68].
Tests performed in plasma or platelet-rich plasma
Thrombin generation (CAT assay)
The Thrombinoscope (Thrombinoscope BC, Netherlands)
can be used to measure thrombin generation (TG) vari-
ables in the presence or absence of platelets. TG is carried
out in a 96-well plate fluorometer. The fluorescence of the
sample is compared to a calibrator. TG variables include
lag-time, maximum thrombin concentration (Cmax), time
required to reach Cmax (Tmax) and endogenous throm-
bin potential (ETP). TG is affected by deficiencies in co-
agulation factors II, V, VIII, IX and X but to a lesser degree
by fibrinogen, FXIII and FVII [69] and the assay is not af-
fected by haemodilution [55].
Overall Hemostasis Potential (OHP)
The overall hemostasis potential (OHP) is a plasma-
based assay based on repeated spectrophotometric regis-
tration of the fibrin-aggregation curve in platelet-poor
plasma containing small amounts of exogenous throm-
bin, tissue-type plasminogen activator, and calcium. The
overall coagulation potential and overall fibrinolytic po-
tential are supplementary parameters of OHP, with stud-
ies reported in a number of hyper- and hypocoagulable
states and during anticoagulant treatment (recently
reviewed in [70]).
Propagation of coagulation
A commercial instrument for detection of propagation
of coagulation in plasma from a TF-coated surface has
been recently introduced and described in several arti-
cles [71-73] (Thrombodynamics Analyzer™, HemaCore,
Russia). Coagulation is detected in a cuvette by time-
lapse image capture of light scattering from the fibrin
network. By image processing and analysis, both the
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(initial rate of clot growth; μm/min) of the coagulation
process can be measured in the same experiment. An
updated version will also measure thrombin generation
in the growing clot utilizing a chromogenic substrate.
Discussion
Several of the assays described are affected by platelet
concentration (e.g. the PFA-100, CPA, VHA’s, and Veri-
fyNow) [5,9,10,18-20]. Multiplate was also shown to be
affected by platelet concentration [74] but another study
reported only a weak correlation within the normal
range [3]. Also haematocrit affect the result of several
methods including VHA’s [18,21]. However, the aggrega-
tion assays have shown to vary in their sensitivity to
haematocrit. The VerifyNow was shown to be affected
by haematocrit [75,76] whereas the effect on the Multi-
plate assay was less pronounced and depended on the
agonist used in the assay [21,77] and the Plateletworks
was not affected at all [6]. The perfusion chambers and
CPA devices require the presence of red blood cells,
which complicates the analysis of platelet suspensions or
samples with a low haematocrit [11,78,79]. Also the
PFA-100 require a haematocrit of >10% [80].
Another difference between the methods is the use
and choice of anti-coagulant which can affect the results.
Several methods including the PFA-100, CPA and Veri-
fyNow use citrated anti-coagulated blood and thus co-
agulation is inhibited by chelation of calcium ions
[5,75,81]. Several anti-coagulants can be used in the per-
fusion chambers and might result in different results de-
pending on the choice of anti-coagulant [14]. The VHA’s
have the advantage that both non-anti-coagulated whole
blood and citrated blood can be used in the assay and
coagulation is allowed in the citrated samples by
addition of calcium. However, if reagents giving longer
clotting times are used, it is important to consider and
avoid unintentional contact activation in the blood col-
lection tubes, as this might otherwise affect the test re-
sults [82]. The PFA-100 is also affected by the blood
group further complicating data interpretations [3]. The
recommended maximum time from blood sampling to
analysis varies between the methods and may also influ-
ence the results and each manufacturer has established
recommendations regarding sample stability.
The VHA’s (TEG, ROTEM and ReoRox) have the ad-
vantage that they can measure coagulation, platelet func-
tion, clot retraction and fibrinolysis simultaneously.
However, in contrast to the aggregation assays, VHA are
in general insensitive to anti-platelet treatment with as-
pirin and ADP-receptor inhibitors with the exception of
the Platelet Mapping assay [34]. PFA-100 has also shown
variable sensitivity to aspirin and variable sensitive to
clopidogrel with the ADP cartridge [80] but a newercartridge called INNOVANCE PFA P2Y has shown
promise in detecting clopidogrel resistance [83]. How-
ever, all aggregation assays, VHA’s, the CPA and PFA-
100 are sensitive to GPIIb/IIIa inhibitors. Despite being
sensitive to anti-platelet treatment the aggregometry as-
says selectively measures platelet function and not clot
formation or fibrinolysis and Multiplate has been shown
to be insensitive to factor deficiencies [84]. Both Multi-
plate and Plateletworks have been shown to be insensi-
tive to fibrinogen [6,74]. The CPA in contrast is affected
by fibrinogen concentration [12]. TG can be used to de-
tect deficiencies in several coagulation factors but is less
sensitive to deficiencies in fibrinogen and FXIII [69]. VHA’s
are affected by fibrinogen concentration [18-20,22] as well
as FXIII [23,24] which allows monitoring of treatment with
fibrinogen and FXIII concentrates [23,24,55,56], although
other methods are still the standard choice in the clinical
setting. Haemodilution-associated coagulopathy can be de-
tected by VHA’s [23,24,27,55,56] and aggregometry [85] but
has not been detectable with TG assay [55].
A main issue to consider is the lack of flow in many of
the assays (e.g. aggregometry and VHA’s) [15]. Also the
ones that operate with flow vary in their shear rates such
as the CPA and PFA-100 [11,12,80]. The shear can be
varied in the flow chambers and can thus mimic in vivo
conditions [14]. However, the perfusion chambers and
CPA have low throughput, are time consuming, compli-
cated to use and evaluate results, and require large sam-
ple volumes, although a number of new commercial
flow chambers and systems are now emerging, overcom-
ing some of these problems [15].
Many of the methods including the aggregation assays
and the PFA-100 have the disadvantage that they are not
suitable for samples with low platelet concentration such
as patients with hematologic malignant disease and thus
are not possible to use to guide prophylactic transfusions
of platelets and to assess the efficacy of a transfusion in
these patients. VHA’s, CPA and flow chambers have
been tested in this context but further studies are war-
ranted [47,78,86-88].
Few of the methods are recommended in guidelines,
the exception is VHA’s in the European guidelines by
“The multidisciplinary Task Force for Advanced Bleed-
ing Care in Trauma” for management of bleeding and
coagulopathy following major trauma where viscoelastic
methods are recommended (Grade 1C) to be performed
to assist in characterizing the coagulopathy and in guid-
ing haemostatic therapy [89].
In the future, new interesting options for haemostasis
testing will become available. A novel cassette-based
TEG instrument is in the pipeline, as well as a better test
for fibrinogen in the ROTEM (FibTEM+). Another trend
is the commercialisation of flow chamber devices, either
as ready-made flow cells or integrated systems with
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T-TAS, VenaFlux, BioFlux and Ibidi systems. The next
step may be even more miniaturised, multi-channel flow
cell devices, as well as devices with patterned surfaces
for platelet adhesion testing. Over the past years, these
devices have evolved from being able to observe shear-
stress induced activation at different shear rates [90] or
changing geometries [91] to devices with patterned sur-
face coatings [92-97] and recently the combination of
the two [98]. One example even includes a simple op-
tical system for detection the onset of coagulation
employing a laser and photodiode [99]. Even though this
device required complex external facilities, it demon-
strates one possibility for detection of coagulation in a
simple point-of-care system, and more will likely follow.
The component that is missing in all current commercial
devices is the endothelium, which is an important compo-
nent of haemostasis in vivo, but complicated to incorporate
in analyses suitable for routine use. Time will tell if addition
of some components from this axis will improve the pre-
dictive power of future “global” haemostasis assays.
Conclusions
No assay available today covers all functions of the
haemostatic process. Therefore, the specific clinical
question and available evidence on diagnostic perform-
ance needs to guide the choice of method. As different
methods have their pros and cons, the laboratory should
choose the method/s giving the most relevant informa-
tion for the requesting clinician, but also one being pos-
sible to perform within the times recommended to
preserve sample stability and reagent performance.
Many of the assays described are still labour intensive
and in their current commercial form not suitable for
high-throughput sample analysis or for use and inter-
pretation by operators with little experience. Therefore,
we would only recommend them to be used in units
where a sufficiently large number of samples are ana-
lysed. One interesting alternative is the possibility for
some of the tests to run the samples in a central lab and
display the results on a screen in the operation theatre.
Another problem is to produce good control materials,
as the elasticity obtained in plasma control samples are
much lower than the ones that will be encountered in
highly elastic samples such as blood and platelet rich
plasma. Many of the tests also propose the use of single
samples, something that in our opinion might be ques-
tionable considering the relatively high variability in
many of the methods, a reliable use of single samples
should first be verified for the actual protocol and in-
strument to be used. Preferably, the normal reference
range to be used should also be established on site with
samples collected, stored and treated in the same way as
the patient samples to be analysed.Competing interests
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